Wegovy HD vs Oral Wegovy: Which Newer Option Fits You?

Novo Nordisk launched two very different versions of Wegovy within a few months of each other, and they answer two different questions. Wegovy HD is a 7.2 mg injection, the strongest semaglutide dose available, built for people who reached the ceiling on 2.4 mg and still need more. Oral Wegovy is a 25 mg daily tablet, the first GLP-1 pill approved for weight loss, built for people who’d rather skip needles. HD produces more weight loss in trials but isn’t a starting point. The pill is a starting option, with a strict morning routine attached. Picking between them is less about which is stronger and more about where you are in treatment and how you want to take it.

What each one actually is

Oral Wegovy reached the market first, approved in December 2025 as a once-daily 25 mg semaglutide tablet. It’s the same active ingredient as the injection, delivered through the stomach using an absorption enhancer. Because that absorption is sensitive, the pill comes with a non-negotiable protocol: take it first thing in the morning on an empty stomach, with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking anything else, or taking other medications.

Wegovy HD followed in March 2026 as a 7.2 mg injection, roughly three times the previous maximum maintenance dose of 2.4 mg. It is a step-up dose, not a starting dose. The label expects you to have tolerated 2.4 mg for at least four weeks and to still need additional weight reduction before moving up. You don’t begin treatment at 7.2 mg.

Head to head

A note on the trial numbers, since they aren’t measured the same way. In STEP UP, the 7.2 mg dose produced about 20.7% mean weight loss under an idealized estimate, closer to 18 to 19% under the more conservative treatment-policy estimate, with roughly one in three participants reaching 25% or more. Oral Wegovy’s OASIS 4 trial landed near 16.6% for fully adherent participants and about 13.6% under the treatment-policy estimate, with 76% reaching at least 5%. Both move the needle; HD simply has more headroom.

The two rules that decide a lot

The first rule is that HD is a destination, not a starting line. If you’ve never taken semaglutide, you can’t begin at 7.2 mg, and a provider won’t prescribe it that way. It’s for the person who titrated all the way up, did well on 2.4 mg, and still has weight to lose.

The second rule is that the pill’s routine is real. The empty-stomach window sounds minor until you map it onto a morning that already includes coffee, breakfast, and other prescriptions. People who take several morning medications often find the 30-minute gap genuinely disruptive, while people with steady routines barely notice it. Be honest about which group you’re in before committing.

Why the durability question matters

Whichever route you choose, the results depend on staying on treatment. This is where the long-term data is reassuring. In the STEP 5 trial, adults with overweight or obesity who stayed on semaglutide 2.4 mg held roughly 15% body-weight loss at two years, well above placebo, showing that the effect persists when treatment continues. Since both Wegovy HD and oral Wegovy deliver the same molecule, the lesson carries: consistency over months, not a sprint, is what produces the outcomes in the headlines.

Consider a scenario where someone has spent a year on 2.4 mg, lost about 15% of their starting weight, then plateaued with another 20 pounds they’d like to lose. HD is the logical next step for that person. Now consider a scenario where someone is brand new to GLP-1s, dreads injections, and keeps a simple morning routine. The pill is the more sensible entry point, even though its ceiling is lower. The “better” drug is the one that matches the situation.

A lower-cost path to the same molecule

Brand-name semaglutide, in either form, isn’t cheap month to month. If cost is the deciding factor, compounded semaglutide is worth understanding, because the active ingredient is the same one in both Wegovy products. TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, across a program range of $179 to $1,579 depending on the medication and plan. For people who want an injectable semaglutide route without the brand-name price, that’s the lane to compare against.

If you’re not sure whether an injection or a pill suits you, the free assessment quiz is a fast way to get matched to an option.

This article is for educational purposes and is not medical advice. Wegovy HD and oral Wegovy carry the same boxed warning for thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN-2. Talk with a licensed healthcare provider before starting or changing any medication.